Hypertension Therapy
Doxazosin can lower atherosclerosis risk in hypertensive patients with insulin resistance
Published in Obesity and Diabetes Week, November 10th, 2003
"Essential hypertension is associated with impairment of both endothelial function and insulin action, and this has provided rationale for the use of anti-hypertensive agents that are at least neutral, if not beneficial, in these areas," endocrinologists in North Ireland explained.
C.H. Courtney and colleagues at Royal Victoria Hospital in Belfast examined "the effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action."
"Sixteen patients with essential hypertension were recruited with 13 (3 men/10...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Survival and Mortality
Mammary grafting increases mediastinitis risk after coronary bypass - Protein Folding
A new molecular culprit found for type 2 diabetes, Alzheimer and Parkinson - Diabetes Pathogenesis
Inflammatory mediators and beta-cell failure link type 1 and 2 diabetes - Genetics and Genomics
MODY is model of genotype/phenotype interactions in type 2 diabetes - Appetite Control
Clinical study of appetite control tablets shows significant results - Birth Defects
Maternal diabetes stalls proper vascular development in embryos - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
